Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done?

JAMA Oncol. 2019 Mar 1;5(3):297-298. doi: 10.1001/jamaoncol.2018.5636.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Biosimilar Pharmaceuticals / adverse effects
  • Biosimilar Pharmaceuticals / economics
  • Biosimilar Pharmaceuticals / therapeutic use*
  • Drug Approval
  • Drug Costs / trends
  • Drug Substitution / trends
  • Drug Utilization / trends
  • European Union
  • Filgrastim / adverse effects
  • Filgrastim / economics
  • Filgrastim / therapeutic use*
  • Hematologic Agents / adverse effects
  • Hematologic Agents / economics
  • Hematologic Agents / therapeutic use*
  • Humans
  • Japan
  • Practice Patterns, Physicians' / economics
  • Practice Patterns, Physicians' / trends*
  • United States

Substances

  • Biosimilar Pharmaceuticals
  • Hematologic Agents
  • Filgrastim